We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Joel Zonszein

Joel Zonszein MD, CDE, FACP, FACE

Professor of Clinical Medicine, Albert Einstein College of Medicine, Department of Medicine, Division of Endocrinology and Metabolism, Montefiore Medical Center The University Hospital for Albert Einstein College of Medicine, Bronx, NY

Dr. Joel Zonszein is Professor of Clinical Medicine at the Albert Einstein College of Medicine and Director of the Clinical Diabetes Center at the University Hospital of the Albert Einstein College of Medicine, a Division of Montefiore Medical Center. He is certified by the American Boards of Internal Medicine, Endocrinology and Metabolism, and Nuclear Medicine.  He has ample clinical experience particularly in the area of diabetes.  In 1993 he developed a large and prominent Clinical Diabetes Center.  Montefiore’s diabetes self-management program, the Proactive Managed Information System for Education in Diabetes (PROMISED©), has been twice nationally recognized by the American Diabetes Association for exemplary performance and the consistent achievement of national standards.  He serves as a faculty member at the Albert Einstein College of Medicine Diabetes Research and Training Program (DRTC) and the Hispanic Center of Excellence (HCOE), and served as a co-investigator and Scientific Director of the Bronx Center to Reduce and Eliminate Ethnic and Racial Health Disparities (BxCREED), all supported by NIH grants. 

He was involved in several of the NIH landmark clinically trials such as the Diabetes Control and Complication Trial (DCCT), the Diabetes Prevention Program (DPP), and the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI2D). His special interest is the understanding of cardiovascular disease in individuals with diabetes with a particular interest in improving diabetes care in underserved minority populations.  He has been instrumental in several projects for diabetes education and diabetes care delivery systems. He serves on several advisory boards, especially those related to improving medical care in ethnically diverse populations. He is a member of several clinical societies and has published broadly. He has lectured extensively in the area of diabetes both nationally and internationally.   Dr. Zonszein is the recipient of many honors and awards.

Disclosures

Dr. Zonszein reports a relationship with the following pharmaceutical companies for years 2011 to 2016:

  • Novo nordisk Speakers Bureau.
  • Takeda Pharmaceuticals North America, Inc. Advisory Board and Speakers Bureau until 2016
  • Merck/Schering-Plough Pharmaceuticals.
  • Janssen, Pharmaceutical Companies of Johnson and Johnson until 2013.
  • Sanofi International Advisory Board.
  • Eli Lilly –Advisory Board until 2014.
  • Behringer Ingelheim-Advisory Board / consultant